First-Line Ipilimumab With Nivolumab Versus Immune Checkpoint Inhibitors With Tyrosine Kinase Inhibitors in Patients With Intermediate- or Poor-Risk Metastatic Clear Cell Renal Cell Carcinoma. jkcvhl 2025, 12 (2), 27-36. https://doi.org/10.15586/jkcvhl.v12i2.387.